EUVIMEDSkopri EUVIMED
CrossrefKarta ta’ informazzjoni

Severe Vitamin D deficiency as a potential contributor to cherry angiomas: A case study and novel hypothesis

Maher Monir Akl, Amr Ahmed

Innovative Medicines & Omics · 2025

DOI: 10.36922/imo.8087 ↗
AstrattDettalji biblijografiċi

Astratt

Cherry angiomas are common benign vascular lesions with a poorly understood underlying pathogenesis. While factors such as aging, hormonal changes, and oxidative stress have been implicated, this case introduces a novel hypothesis linking severe Vitamin D deficiency to the development of cherry angiomas. We report the case of a 27-year-old Arab female with no medical, genetic, or familial predisposition to cherry angiomas. The patient presented with multiple asymptomatic, erythematous, dome-shaped lesions localized to the breast and neck regions. Comprehensive laboratory evaluations were unremarkable except for severe Vitamin D deficiency, with a serum level of 3 ng/mL (normal: 30 – 100 ng/mL). Vitamin D deficiency is known to disrupt endothelial function, increase oxidative stress, and upregulate pro-angiogenic mediators such as vascular endothelial growth factor. These molecular disturbances may promote capillary proliferation and vascular instability, providing a plausible mechanism for the sudden onset of cherry angiomas in this patient. This case highlights the importance of Vitamin D in vascular health and proposes a potential link between its deficiency and the pathogenesis of cherry angiomas. Further research is warranted to explore this relationship and elucidate the underlying molecular mechanisms, which may offer new insights into the prevention and management of cherry angiomas in patients with Vitamin D deficiency.

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.

Ara t-tariffi →